From Detection To Direction: Enhanced Reporting To Make Your Lab Indispensable

The accuracy of PCR has significantly advanced the molecular testing landscape, but the way it is reported often falls short of providing targeted guidance to aid in clinical decision-making. That leaves providers to sort through resistance genes and pathogen detections on their own, then navigate elsewhere to weigh them against complex, evolving guidelines.

To bridge that gap, Streamline Scientific is introducing a new reporting add-on with clinical context. Built directly on top of your existing PCR results, our new add-on goes beyond standard detection-only reporting to translate those findings into insights and add the latest CLSI M100 guidelines.

Positive Impacts Across the Chain of Care

Enhanced reporting has the potential to improve care at all levels—for the laboratory, clinicians, and patients themselves.

• For labs: Differentiating is critical in a competitive market. Our new add-on enables you to 
  upgrade your services without investing in new platforms, instruments, or software. And 
  because it layers on top of existing PCR workflows, implementation is seamless with your 
  LIS. Reports can even be white-labeled, so clients see them as part of your lab’s value 
  offering rather than a separate product.
• For clinicians: Providers are increasingly looking to their lab partners for more than just raw data—they want insights that can be immediately applied at the point of care. 
  Instead of manually cross-referencing resistance markers against guidelines, 
  they receive a patient-specific report that clearly outlines which antibiotic resistance and 
  alternatives
• For patients: In an era when antibiotic resistance is one of the most urgent public health challenges, reducing guesswork in prescribing isn’t just convenient—it’s essential. 
  Better data for providers means patients experience less trial-and-error prescribing and
  quicker access to precision therapeutics that lower the risk of antibiotic resistance. 

Built on A Standard You Can Trust

Antibiotic guidelines should come from a trusted and established resource. This is why our add-on reporting service is based directly on the Clinical and Laboratory Standards Institute’s (CLSI) M100 guidelines, the gold standard for antimicrobial susceptibility testing.

This means that insights are evidence-based, free of added lab interpretation, and regularly updated to reflect best practices in the evolving landscape of antibiotic resistance. Streamline’s reporting contextualizes this information alongside patient-specific PCR results to provide clarity.

Key Features of the Reporting Add-On

• Multi-pathogen analysis: Can account for complex infections using our advanced 
  pathogen-specific algorithm.

• Actionable insights for providers: Clearly identifies drugs to avoid, mapped to each
  pathogen and resistance marker.
• Integration without disruption: Works as an add-on to your existing PCR reports, requiring 
  no new instrumentation or LIS overhaul.
• Clinically validated context: Antibiotic insights are transparently aligned with the 
  CLSI M100 guidelines, not proprietary rules.
• Custom branding options: Comes white-label ready, so reports can carry your lab’s name
  and reinforce your client relationships.
• Supports antibiotic stewardship: Helps clinicians reduce unnecessary or ineffective 
  prescribing, supporting better patient care and public health.

Going From Vendor to Vital Resource

In molecular diagnostics, reporting should do more than confirm what’s present—it should help guide what happens next and cement your role as a clinical partner. Position your lab as an indispensable asset by enhancing your clients’ ability to weigh unique patient cases alongside a trusted resource.

Enhanced reporting is a small change that can have a big impact on outcomes, antibiotic stewardship, and the overall value your lab provides.

Want to see how it works in practice?